Testosterone Enanthate: Dosage, Injection Schedule, and How It Compares to Other TRT Forms

What Is Testosterone Enanthate and How Does It Work?

Testosterone enanthate is a synthetic ester of testosterone in which the enanthate (heptanoate) chain is covalently bonded to the C-17 hydroxyl group of the testosterone molecule. After an intramuscular or subcutaneous injection, depot oil is absorbed slowly from the injection site, and esterases in the bloodstream cleave the ester chain to release free testosterone. The released hormone is biologically identical to endogenous testosterone: it binds androgen receptors in muscle, bone, the central nervous system, and other target tissues.

The enanthate ester produces a half-life of approximately 8 to 10 days in humans, which means a single dose sustains supraphysiologic or mid-normal testosterone concentrations for roughly two weeks before trough levels drop below the therapeutic range [1]. This pharmacokinetic profile is the core reason clinicians favor twice-monthly or weekly schedules for TRT rather than daily dosing.

The FDA first approved Delatestryl (testosterone enanthate 200 mg/mL in sesame oil) for primary and hypogonadotropic hypogonadism in 1953. In September 2018 the FDA approved Xyosted, a prefilled autoinjector of testosterone enanthate for weekly subcutaneous injection, marking the first subcutaneous testosterone enanthate product specifically indicated for adult male hypogonadism [2].

Hypogonadism is defined by the American Urological Association (AUA) as a morning serum total testosterone consistently below 300 ng/dL measured on at least two separate occasions, accompanied by signs or symptoms such as reduced libido, fatigue, depressed mood, or reduced muscle mass [3].

Standard Dosage and Injection Schedule

For most men receiving TRT, testosterone enanthate is initiated at 100 to 200 mg intramuscularly every 14 days, or 50 to 100 mg every 7 days. Weekly injections produce smaller peak-to-trough fluctuations, which many patients report as fewer mood or energy swings.

The Xyosted autoinjector starts at 75 mg subcutaneously once weekly. After four weeks, clinicians measure a trough testosterone level (drawn within 24 hours before the next injection) and adjust to 50 mg or 100 mg depending on the result. The prescribing information specifies a target trough of 300, 1 to 050 ng/dL, the normal physiologic range [2].

Practical injection options include:

• Intramuscular (IM): Vastus lateralis (outer thigh) or gluteus medius, using a 23, 25 gauge, 1, 1.5-inch needle.
• Subcutaneous (SC): Abdomen or outer thigh, using a 27, 29 gauge, 0.5-inch needle. SC injection produces slower absorption and may reduce peak-to-trough swings compared with IM in some patients [4].

The HealthRX clinical team uses a three-tier titration framework for testosterone enanthate:

Tier 1 (initiation): 100 mg IM or 75 mg SC weekly for 8 weeks. Draw trough labs at week 8. Tier 2 (adjustment): If trough is <400 ng/dL, increase dose by 25 to 50 mg. If trough exceeds 700 ng/dL, reduce by 25 mg or extend interval to 10 days. Tier 3 (maintenance): Once two consecutive troughs fall within 400 to 700 ng/dL, recheck every 6 months with a complete metabolic panel, hematocrit, PSA, and estradiol.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest using testosterone formulations that maintain serum testosterone levels within the normal range for healthy young men (400 to 700 ng/dL for most assays)" [5].

Testosterone Enanthate vs. Testosterone Cypionate

The question clinicians and patients ask most is whether enanthate or cypionate is the better injectable. The short answer is that they are pharmacologically near-identical for TRT purposes.

Testosterone cypionate carries a cyclopentylpropionate ester (8 carbons) vs. the heptanoate ester of enanthate (7 carbons). That one-carbon difference translates to a half-life of approximately 10 to 12 days for cypionate vs. 8 to 10 days for enanthate [1]. In a real-world TRT injection schedule, this distinction rarely changes clinical outcomes. Both are dissolved in oil (cypionate typically in cottonseed oil; enanthate in sesame or castor oil), both are injected IM or SC, and both yield the same free testosterone once the ester is cleaved.

Two practical differences do exist. Testosterone cypionate is manufactured domestically in the United States in large volumes, making it marginally less expensive and more consistently available at U.S. retail pharmacies. Testosterone enanthate, particularly Xyosted, may carry a higher out-of-pocket cost without insurance. Outside the United States, enanthate is the more widely prescribed formulation. A 2020 review in the journal Andrology noted that testosterone enanthate remains the most commonly prescribed injectable testosterone globally [6].

A patient switching from cypionate to enanthate at an equivalent milligram dose will see nearly identical trough and peak testosterone values. No dose adjustment is required when switching between these two esters at the same milligram-per-week schedule.

Testosterone Enanthate vs. Testosterone Propionate

Testosterone propionate carries a 3-carbon propionic acid ester, producing a half-life of only 0.8 to 1.5 days [1]. That short duration forces patients to inject every 1 to 3 days to maintain stable levels. Stable testosterone is desirable: erratic peaks and troughs can drive fluctuations in mood, libido, and hematocrit.

For TRT (as opposed to bodybuilding protocols), propionate is rarely a first-line choice precisely because of this injection burden. A man on propionate might inject 25 to 50 mg every other day, completing 3, 4 injections per week. Most patients on enanthate inject once or twice per week. Over one year, enanthate users complete roughly 52, 104 injections; propionate users may complete 150, 180. The cumulative injection-site burden matters for adherence.

Propionate also carries a higher incidence of injection-site pain, thought to be related to both the shorter ester and its common diluents. A 2014 case series published in JAMA Dermatology documented cutaneous reactions at injection sites in men using short-ester testosterone formulations [7]. Pain is reported less frequently with enanthate in sesame oil.

Propionate does hold one clinical niche: it leaves the body more quickly, which can be useful in the rare scenario where a patient needs to discontinue testosterone fast (e.g., preparing for fertility treatment). For standard long-term TRT, enanthate is the better practical choice.

Testosterone Enanthate vs. Testosterone Pellets

Testosterone pellets (brand: Testopel) are crystalline cylinders of testosterone USP implanted subcutaneously in the upper gluteal region or hip under local anesthesia. Each pellet contains 75 mg of testosterone. Clinicians typically implant 6, 12 pellets (450 to 900 mg total) every 3 to 6 months, depending on individual metabolism [8].

The appeal of pellets is clear: no weekly injections. Many men prefer a procedure every four to six months over self-injection. However, pellets carry procedural risks absent from injectable formulations, including infection at the insertion site (reported in approximately 1 to 3% of cases), pellet extrusion (2 to 10%), and fibrosis with repeated insertions [8].

Pellets produce a gradual serum testosterone rise over weeks 1, 4, a plateau phase, then a slow decline toward the end of the dosing interval. That decline means some men experience a "low T" window in month 4, 6 that does not occur with consistent weekly injections of enanthate. Dose titration with pellets is also imprecise: if a patient is over-dosed, clinicians cannot remove a pellet easily. With injectable enanthate, the physician adjusts the next dose instantly.

For men who cannot or will not self-inject, pellets are a reasonable alternative. For those comfortable with injections, enanthate provides tighter hormonal control.

Testosterone Enanthate vs. Testosterone Gel (AndroGel)

AndroGel (testosterone 1% or 1.62%) is applied daily to the shoulders, upper arms, or abdomen and absorbed transdermally. The FDA approved AndroGel 1% in 2000 for male hypogonadism. The 1.62% formulation followed in 2011 [9].

Gels produce a daily steady-state testosterone profile with minimal peak-to-trough variation. This can be favorable for men who are sensitive to hormonal fluctuations. However, transdermal absorption varies considerably between individuals: a 2016 study in the Journal of Clinical Endocrinology and Metabolism found that only approximately 9 to 14% of applied testosterone gel dose reaches systemic circulation, with inter-individual variability wide enough that some men never achieve therapeutic levels despite maximum labeled doses [10].

The transfer risk is a meaningful clinical concern. If a gel-treated man makes skin-to-skin contact with a partner or child before the gel dries completely (typically 2 to 5 hours), testosterone can transfer. The FDA issued a black-box warning for all topical testosterone products specifically about this secondary exposure risk [9].

Injectable testosterone enanthate carries no transfer risk and, at standard doses, produces more predictable serum testosterone concentrations than gels in most patients. The trade-off is the weekly or biweekly injection itself.

Cost also differs substantially. A month's supply of AndroGel 1.62% at a retail pharmacy runs $400, $600 without insurance. Generic testosterone enanthate 200 mg/mL vials cost $30, $80 per month at compounding or retail pharmacies, making injectables far more affordable for uninsured or underinsured patients.

Clinical Benefits of Testosterone Replacement Therapy

The evidence base for TRT in hypogonadal men spans decades. The landmark Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 or older with a serum testosterone below 275 ng/dL, demonstrated that one year of testosterone therapy produced statistically significant improvements in sexual function, bone density, and anemia [11].

Specifically:

• The Sexual Function Trial within TTrials (N=470) showed testosterone produced a mean increase of 2.64 points on the Derogatis Interview for Sexual Functioning score vs. placebo (P<0.001) [11].
• The Bone Trial within TTrials (N=247) showed testosterone increased volumetric bone mineral density of the spine by 7.5% vs. 0.8% in the placebo group (P<0.001) [12].
• A 2023 meta-analysis of 35 randomized controlled trials (N=5,609) published in JAMA Network Open found that TRT reduced fasting glucose by a mean of 0.56 mmol/L and improved lean body mass by 1.6 kg compared with placebo in hypogonadal men [13].

The Endocrine Society guideline notes: "We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density" [5].

Side Effects and Safety Monitoring

Testosterone enanthate shares the same side-effect profile as other injectable testosterone formulations. The most clinically significant adverse effects include:

Erythrocytosis: Testosterone stimulates erythropoietin production, raising hematocrit. Hematocrit above 54% increases thrombotic risk. The Endocrine Society recommends checking hematocrit at baseline, 3 to 6 months after initiation, and annually thereafter, and reducing dose or frequency if hematocrit exceeds 54% [5].

Suppression of spermatogenesis: Exogenous testosterone suppresses LH and FSH through negative feedback, reducing intratesticular testosterone and sperm production. Men wishing to preserve fertility should not use testosterone without concurrent gonadotropin therapy (typically human chorionic gonadotropin, hCG) or should consider alternatives such as clomiphene citrate [3].

Estradiol elevation: Testosterone aromatizes to estradiol in adipose tissue. Elevated estradiol can cause gynecomastia, water retention, and mood changes. Monitoring estradiol (sensitive assay, target <40 pg/mL on most TRT protocols) helps guide aromatase inhibitor use when necessary.

Acne and oily skin: Androgenic stimulation of sebaceous glands is common. Most cases are mild and manageable with standard topical therapy.

Injection-site reactions: Particularly with IM injections, pain, induration, or nodules may develop. Rotating injection sites and warming the oil before injection reduce discomfort.

Cardiovascular considerations: The TRAVERSE trial (N=5,246 hypogonadal men at elevated cardiovascular risk, mean follow-up 33 months) found testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE), with a hazard ratio of 0.96 (95% CI 0.78, 1.17) [14]. However, the trial did find a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, results that the FDA incorporated into updated labeling in 2024 [14].

Prostate safety monitoring remains standard. PSA should be checked at baseline and at 3 to 6 months, with urology referral if PSA rises more than 1.4 ng/mL above baseline within 12 months [3].

Who Is a Candidate for Testosterone Enanthate?

A candidate for testosterone enanthate-based TRT is an adult man with:

1. Morning total testosterone below 300 ng/dL on two separate measurements.
2. At least one consistent symptom of hypogonadism (reduced libido, fatigue, depressed mood, reduced muscle mass, or increased body fat).
3. No active prostate or breast cancer, no hematocrit above 54% at baseline, no untreated severe obstructive sleep apnea, and no current desire for biological paternity without concurrent fertility-preserving agents [5].

Age alone does not disqualify a patient. The AUA acknowledges that late-onset hypogonadism (age-related testosterone decline) is a legitimate indication when biochemical and clinical criteria are both met [3].

Men who prefer to avoid weekly self-injections may be better served by pellets or gels. Men who want precise titration, lower cost, and no procedural risk are generally best served by injectable enanthate or cypionate.

Starting TRT With Testosterone Enanthate: Practical Steps

The path from diagnosis to first injection typically follows these steps:

Step 1. Labs. Draw total testosterone (8, 10 a.m.), free testosterone, LH, FSH, estradiol, prolactin, CBC with hematocrit, PSA, and a comprehensive metabolic panel. Repeat total testosterone on a separate morning to confirm.

Step 2. Physician review. A board-certified clinician reviews labs against symptoms. If both criteria are met, a prescription is written for testosterone enanthate 200 mg/mL (multi-dose vial) or Xyosted prefilled autoinjector.

Step 3. Injection training. Patients learn IM injection technique (ventrogluteal or vastus lateralis) or SC technique for Xyosted. The HealthRX care team provides a video-guided training module at onboarding.

Step 4. First follow-up labs. Trough testosterone drawn at week 6, 8, before the next scheduled injection. Hematocrit and estradiol checked at the same time.

Step 5. Dose adjustment. Dose is increased or decreased in 25 to 50 mg increments based on trough level and symptom response, targeting a trough of 400 to 700 ng/dL per Endocrine Society guidance [5].

Step 6. Long-term monitoring. Once stable, lab panels every 6 months for year one, then annually if levels remain consistent.